> Detailanzeige

Smith, Kyle D.; Achan, Beatrice; Hullsiek, Kathy Huppler; McDonald, Tami R.; Okagaki, Laura H.; Alhadab, Ali A.; Akampurira, Andrew; Rhein, Joshua R.; Meya, David B.; Boulware, David R.; Nielsen, Kirsten; Musubire, Abdu; Nabeta, Henry W.; Williams, Darlisha A.; Morawski, Bozena; Rolfes, Melissa A.; Ndyetukira, Jane Francis; Ahimbisibwe, Cynthia; Kugonza, Florence; Sadiq, Alisat; Dyal, Jonathan; Neborak, Julie M.; King, Alexa M.; Yueh, Nathan; [...]

Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda
  • Beteiligte: Smith, Kyle D.; Achan, Beatrice; Hullsiek, Kathy Huppler; McDonald, Tami R.; Okagaki, Laura H.; Alhadab, Ali A.; Akampurira, Andrew; Rhein, Joshua R.; Meya, David B.; Boulware, David R.; Nielsen, Kirsten; Musubire, Abdu; Nabeta, Henry W.; Williams, Darlisha A.; Morawski, Bozena; Rolfes, Melissa A.; Ndyetukira, Jane Francis; Ahimbisibwe, Cynthia; Kugonza, Florence; Sadiq, Alisat; Dyal, Jonathan; Neborak, Julie M.; King, Alexa M.; Yueh, Nathan; [...]
  • Erschienen: American Society for Microbiology, 2015
  • Erschienen in: Antimicrobial Agents and Chemotherapy, 59 (2015) 12, Seite 7197-7204
  • Sprache: Englisch
  • DOI: 10.1128/aac.01299-15
  • ISSN: 0066-4804; 1098-6596
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: ABSTRACT Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia. Yet, knowledge is limited of current antimicrobial resistance in Africa. We examined antifungal drug susceptibility in 198 clinical isolates collected from Kampala, Uganda, between 2010 and 2014 using the CLSI broth microdilution assay. In comparison with two previous studies from 1998 to 1999 that reported an MIC 50 of 4 μg/ml and an MIC 90 of 8 μg/ml prior to widespread human fluconazole and agricultural azole fungicide usage, we report an upward shift in the fluconazole MIC 50 to 8 μg/ml and an MIC 90 value of 32 μg/ml, with 31% of isolates with a fluconazole MIC of ≥16 μg/ml. We observed an amphotericin B MIC 50 of 0.5 μg/ml and an MIC 90 of 1 μg/ml, of which 99.5% of isolates (197 of 198 isolates) were still susceptible. No correlation between MIC and clinical outcome was observed in the context of amphotericin B and fluconazole combination induction therapy. We also analyzed Cryptococcus susceptibility to sertraline, with an MIC 50 of 4 μg/ml, suggesting that sertraline is a promising oral, low-cost, available, novel medication and a possible alternative to fluconazole. Although the CLSI broth microdilution assay is ideal to standardize results, limit human bias, and increase assay capacity, such assays are often inaccessible in low-income countries. Thus, we also developed and validated an assay that could easily be implemented in a resource-limited setting, with similar susceptibility results ( P = 0.52).
  • Zugangsstatus: Freier Zugang